Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

XenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform


News provided by

The START Center for Cancer Research

02 Oct, 2025, 12:01 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
START Research Logo
This image opens in the lightbox
XenoSTART
This image opens in the lightbox
Minerva Imaging

Expanded partnership positions XenoSTART and Minerva Imaging at the forefront of radiopharmaceuticals — one of the fastest-growing areas in oncology drug development.

SAN ANTONIO and COPENHAGEN, Denmark, Oct. 2, 2025 /PRNewswire/ -- The START Center for Cancer Research ("START"), its preclinical division XenoSTART, and Minerva Imaging today announced an expansion of their decade-long partnership to establish the industry's most comprehensive integrated platform for radiopharmaceutical drug development. This collaboration unites XenoSTART's repository of clinically annotated patient-derived xenograft (PDX) models with Minerva Imaging's advanced molecular imaging and radionuclide therapy expertise, creating a single-source solution spanning discovery, translational research, and manufacturing.

Radiopharmaceuticals are one of the fastest-growing areas in oncology, redefining how we treat cancer by precisely targeting tumors while sparing healthy tissue. In metastatic prostate cancer, these therapies are already changing standards of care and are now being explored in earlier disease stages and across other high-burden indications such as breast and neuroendocrine tumors. This expansion is driving an urgent need for robust, translational platforms that can shorten timelines and de-risk development.

"By combining XenoSTART's deep expertise in clinically annotated PDX models with Minerva Imaging's state-of-the-art facilities for radiopharmaceutical drug development, we are delivering the gold standard in translational oncology research to target cancers such as prostate," said Nick Slack, MBE, Chairman and CEO of START. "For sponsors, this means faster, smarter, and more predictable development of life-changing therapies that ultimately bring positive impact to patients who need them most."

Minerva Imaging operates as a fully integrated CRO and CDMO specialized in radiopharmaceuticals. Leveraging more than two decades of expertise in oncology and molecular imaging, Minerva Imaging provides comprehensive imaging modalities (PET/CT, SPECT/CT, MRI), advanced orthotopic in-vivo models, and GMP-certified manufacturing infrastructure for radiopharmaceuticals. This integration enables precise validation of therapeutic mechanisms and supports seamless progression of candidates from preclinical evaluation through clinical translation.

Carsten H. Nielsen, PhD, Co-founder and CEO of Minerva Imaging, shared, "Our mission is to accelerate the development of novel radiopharmaceuticals through advanced imaging, radionuclide therapy expertise, and GMP manufacturing. By strengthening our collaboration with XenoSTART and START, we are creating a powerful translational bridge for collaborators to move promising therapies from bench to bedside with unprecedented speed and confidence."

XenoSTART's PDX models are uniquely differentiated by being derived exclusively from tissue obtained from patients treated across START's global network. These models ensure representation of the most clinically relevant disease states and capture resistance patterns and treatment histories that closely mirror real-world patient populations. Michael Wick, PhD, Chief Scientific Officer of XenoSTART, added, "XenoSTART provides the most predictive preclinical platform in the industry. Expanding our work with Minerva Imaging ensures that sponsors benefit from seamless integration of these models with advanced radiopharmaceutical development, particularly in prostate cancer where the clinical need is acute."

Together, START, XenoSTART, and Minerva Imaging are setting a new standard for radiopharmaceutical drug development — accelerating discovery, reducing risk, and delivering therapies that matter most to patients.

About The START Center for Cancer Research

Deeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START clinical trial sites have conducted more than 1,000 early-phase clinical trials, including for 45 therapies that were approved by the FDA or EMA. START represents the world's largest roster of early-phase principal investigators across its 12 clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world. Learn more at STARTresearch.com.

About XenoSTART

XenoSTART is the preclinical research division of the START network dedicated to advancing translational oncology. XenoSTART develops and maintains one of the world's most comprehensive collections of patient-derived xenograft (PDX) models, representing a wide range of cancer types and disease stages. Each model is clinically annotated with detailed treatment histories, genomic and histologic characterization, and in vivo drug sensitivity data, enabling researchers to bridge the gap between bench and bedside. Through its close integration with START's global network of early-phase clinical trial sites, XenoSTART offers unique access to fresh patient tumor tissue, rapid model development, and clinically relevant insights that accelerate drug discovery and development. Learn more at https://startresearch.com/preclinical/. 

About Minerva Imaging

Minerva Imaging is a fully integrated CRO and CDMO specialized in targeted radionuclide therapies. The company focuses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. Minerva's competences are built on over 25 years of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. Follow Minerva Imaging on LinkedIn (https://www.linkedin.com/company/minerva-imaging) for the latest news updates or visit www.minervaimaging.com for more information.

Media Contacts:

Lauren Panco
Vice President, Marketing
Lauren.panco@startresearch.com
609-216-4920

Lisa Osborne
PR Consultant  
Rana Healthcare Solutions
lisa@ranahealth.com 

Fabian Pruissen
Senior Business Developer
fbu@minervaimaging.com 

Logo - https://mma.prnewswire.com/media/2492565/START_Research__Logo.jpg
Photo - https://mma.prnewswire.com/media/2787142/Xenostart_Logo_Full_Color.jpg
Photo - https://mma.prnewswire.com/media/2787524/Minerva_Imaging_logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.